At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 104 enrolled
Drug / intervention
edaravonedrug
Likely dose
edaravone 30mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effects of Edaravone in Patients With Acute Myocardial Infarction
In Brief
A Phase 4 clinical trial evaluating edaravone for Myocardial Infarction and Reperfusion Injury. Completed, enrolled 104 participants across 1 site.
Detailed Summary
Early reperfusion therapy has improved the clinical outcomes of patients with acute myocardial infarction (AMI), but these benefits are limited in some patients by reperfusion injuries. There is now increasing evidence that reactive oxygen species cause reperfusion injury. This study was designed to examine the effects of edaravone, a novel free radical scavenger, in patients with AMI.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyocardial Infarction, Reperfusion Injury
CountriesJapan
CollaboratorsJapan Heart Foundation
Timeline
Phase 4CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartApr 2001
First PostedDec 2005
Study CompletionJun 2007
TodayJul 2026
First PostedDec 14, 2005
Enrollment StartApr 1, 2001
Study CompletionJun 1, 2007
TodayJul 2, 2026
Posted 20.6 years ago
Interventions
edaravonedrug
intravenous administration of 30mg Edaravone just before reperfusion therapy